Italy cannabis ALS trial

Italy has enrolled the first participant in a 3-year Phase 2 trial of Avextra’s cannabis medicine for Amyotrophic Lateral Sclerosis (ALS), Parkinson’s, and Alzheimer's. The 180-person study will compare a standardized full-spectrum extract to placebo to check safety and whether it eases symptoms and improves daily life. For ALS, the goal is less pain, better sleep, and steadier mood.